CONCLUSIONS
With clear benefits defined by eradicating HCV infection
from the body, including decreased rates of hepatic decompensation
and HCC, the new DAA agents represent a significant
opportunity for the infected populations, for both
treatment-naïve patients and those for whom previous treatment
efforts failed. Acting now is essential. Identifying
patients with chronic hepatitis C that need to be treated is
critical, and prompt referrals to specialists in hepatology or
gastroenterology is advised. Practitioners of patients preparing
to start therapy must be prepared to anticipate side effects, actively manage the symptoms, and support the
patient throughout the treatment process.